Vol. 4, Issue 3, 2020August 30, 2020 CDT
Apparent deficiencies in the phase III data for Seres Therapeutics, SER-109: a closer inspection of the data prior to a decision by the FDA expert committee.
Apparent deficiencies in the phase III data for Seres Therapeutics, SER-109: a closer inspection of the data prior to a decision by the FDA expert committee.
Mikaela Bullari, Jonathan Darauay, Khadijah Edhi, Karen Elizondo, Leen Elyas, Hermela Gebregzabher, Vanessa Griffin, Zahra Khan, Daniela Lopez, Grace Nguyen, Job Oganda, Sana Omar, Shireesh Apte,
Bullari, Mikaela, Jonathan Darauay, Khadijah Edhi, Karen Elizondo, Leen Elyas, Hermela Gebregzabher, Vanessa Griffin, et al. 2020. “Apparent Deficiencies in the Phase III Data for Seres Therapeutics, SER-109: A Closer Inspection of the Data Prior to a Decision by the FDA Expert Committee.” Journal of High School Science 4 (3). https://doi.org/10.64336/001c.16766.